超声内镜引导下消融与单纯监测对胰腺囊性病变结局的比较:倾向性评分匹配研究(附视频)
该回顾性研究纳入169例接受超声内镜引导下快速乙醇灌洗(EUS-REL)和610例单纯监测(SO)的胰腺囊性病变患者,经倾向性评分匹配形成159对。EUS-REL组10年BD-IPMN进展累积发生率显著低于SO组(1.6% vs 21.2%;HR 12.35;P=0.003),手术切除率有降低趋势,10年总生存率和疾病特异性生存率两组相当。
要点
- EUS-REL组影像学完全缓解率为74%,操作相关胰腺炎发生率为13.0%(22例,19例轻度、3例中度),无严重不良事件报告。
- EUS-REL组10年BD-IPMN进展累积发生率显著低于SO组(1.6% vs 21.2%;HR 12.35;P=0.003)。
- EUS-REL组手术切除率较SO组有降低趋势,10年总生存率和疾病特异性生存率两组相当。
核心结论
- 对于增大的疑似BD-IPMN或直径>3 cm且不适合手术的PCLs患者,EUS-REL与10年BD-IPMN进展累积发生率显著降低相关,手术切除率有降低趋势,10年OS和DSS与SO相似。
- 作者认为EUS-REL可能是不适合手术的增大的疑似BD-IPMN或>3 cm PCLs患者管理时SO的可行替代方案。
研究设计与样本
- 回顾性研究,纳入接受EUS-REL(2015-2022年)或SO(2007-2022年)的PCLs患者,包括增大的疑似BD-IPMN或直径>3 cm且不适合手术者。
- EUS-REL组169例,SO组610例,倾向性评分匹配后形成159对。
- EUS-REL为即时乙醇灌洗4次。
- 主要结局为BD-IPMN进展的累积发生率。
主要发现
- EUS-REL组影像学完全缓解率为74%。
- EUS-REL组操作相关胰腺炎发生率为13.0%(n=22;19例轻度、3例中度),无严重不良事件报告。
- EUS-REL组10年BD-IPMN进展累积发生率显著低于SO组(1.6% vs 21.2%;风险比12.35;P=0.003)。
- EUS-REL组手术切除率较SO组有降低趋势。
- 两组10年OS和10年DSS率相当。
临床怎么用
- 作者认为EUS-REL可能是不适合手术的增大的疑似BD-IPMN或>3 cm PCLs患者管理时SO的可行替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: EUS-guided ethanol ablation is a recently introduced treatment approach for pancreatic cystic lesions (PCLs), including branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs). However, the utility of this procedure is limited because of its relatively low efficacy in treating PCLs. METHODS: We retrospectively reviewed patients with PCLs, including those with enlarging suspected BD-IPMNs or those with PCLs measuring >3 cm, who were suboptimal candidates for surgery and had been managed using EUS-guided rapid ethanol lavage (EUS-REL; immediate ethanol lavage performed 4 times, 2015-2022) or surveillance only (SO; 2007- 2022). Propensity score matching (PSM) was performed to minimize bias. The primary outcome was the cumulative incidence rate of BD-IPMN progression. Secondary outcomes were the efficacy and safety of EUS-REL, surgical resection rate (SR), overall survival (OS), and disease-specific survival (DSS) in both groups. RESULTS: Overall, 169 and 610 patients were included in the EUS-REL and SO groups, respectively. PSM created 159 matched pairs. The radiologic complete resolution rate after EUS-REL was 74%. Procedure-related pancreatitis in the EUS-REL group was 13.0% (n = 22; 19 mild and 3 moderate grade); no severe adverse events were reported. The 10-year cumulative incidence rate of BD-IPMN progression was significantly lower in the EUS-REL group than in the SO group (1.6% vs 21.2%; hazard ratio, 12.35; P = .003). EUS-REL showed a lower tendency of SR compared with that associated with SO. The rates of 10-year OS and 10-year DSS were comparable in both groups. CONCLUSIONS: EUS-REL was associated with a significantly lower 10-year cumulative incidence rate of BD-IPMN progression and a lower tendency of SR, whereas its 10-year OS and DSS rates were similar to those of SO for PCLs. EUS-REL may be a viable alternative to SO for managing patients with enlarging suspected BD-IPMNs or those with PCLs >3 cm who are suboptimal candidates for surgery.
引用
- Song YJ, Huh G, Kim EH, et al. Comparison of outcomes of EUS-guided ablation and surveillance only for pancreatic cystic lesions: a propensity score-matching study (with videos). Gastrointest Endosc. 2023. PMID: 37211286. doi:10.1016/j.gie.2023.05.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。